Development of alkyl glycerone phosphate synthase inhibitors: Structure-activity relationship and effects on ether...

Area of Science:

• Biochemistry
• Oncology
• Medicinal Chemistry

Background:

• Alkylglyceronephosphate synthase (AGPS) is crucial for ether phospholipid metabolism, promoting cancer cell proliferation and motility in aggressive tumors.
• Structure-activity relationship (SAR) studies identified a potent AGPS inhibitor, 2i, with enhanced in vitro binding affinity compared to its predecessor.

Purpose of the Study:

• To evaluate the efficacy of the AGPS inhibitor 2i in targeting cancer cell proliferation, migration, and epithelial to mesenchymal transition (EMT).
• To confirm the AGPS-dependent mechanism of action for 2i's effects on EMT.

Main Methods:

• In vitro binding affinity assays.
• Cellular assays in 231MFP, PC-3, and MDA-MB-231 cancer cells to assess ether lipid levels, cell migration, and EMT markers (E-cadherin, Snail, MMP2).
• Combination studies with AGPS-targeting siRNAs.

Main Results:

• Compound 2i reduced ether lipid levels and cell migration in 231MFP cells.
• 2i specifically impaired EMT in PC-3 and MDA-MB-231 cells by modulating E-cadherin, Snail, and MMP2 expression.
• No additive effect was observed when 2i was combined with AGPS siRNAs, confirming AGPS dependency.
• 2i inhibited proliferation in MDA-MB-231 cells with high AGPS expression and showed negligible effects on non-tumorigenic MeT5A cells, indicating cancer specificity.

Conclusions:

• The AGPS inhibitor 2i demonstrates potent anti-cancer properties by disrupting ether lipid metabolism and inhibiting EMT.
• 2i exhibits cancer-specific effects, highlighting its potential as a targeted therapeutic agent for aggressive tumors.
• The findings validate AGPS as a therapeutic target for cancer treatment.